Biodesix BDSX 深 沪
等待开盘 08-21 09:30:00 美东时间
24.03
-1.510
-5.91%
华盛通- 最 高26.00
- 今 开25.20
- 成交量 22.92万股
- 最 低 23.76
- 昨 收 25.54
- 总市值 2.54亿
- 52周最高 26.3999
- 市盈率 静 --
- 换手率 2.17%
- 52周最低 5.26
- 委 比 0.00%
- 总股本 1055.11万
- 历史最高 639.80
- 量 比 2.31
- 振 幅 8.77%
- 历史最低 3.436
- 每 手 1
- 风险率 5.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biodesix Earnings Call Highlights Rapid Growth Path
Biodesix, Inc. (($BDSX)) has held its Q2 earnings call. Read on for the main hi...
08-17 08:23
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.
08-07 02:34
Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
Biodesix, Inc. announced that its leadership team will participate in a fireside chat and host investor meetings at Canaccord Genuity’s 46th Annual Growth Conference on August 11-12, 2026. The fireside chat will take place on August 12 at 3:30 PM ET in Boston, MA. Biodesix, a leading diagnostic solutions company, offers tests like Nodify Lung® and IQLung® to improve outcomes for lung disease patients. The presentation will be available via webcas...
08-04 10:00
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
Biodesix, Inc. (Nasdaq: BDSX) announced it will release its second-quarter 2026 financial results after market close on August 5, 2026. Management will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update. Registration links for the webcast and Q&A session are available. Biodesix is a leading diagnostic solutions company focused on improving clinical care and patient outcomes thro...
07-22 10:00
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32
Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $32.
06-25 19:00
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
HC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26
HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $26.
06-15 18:17
